Author:
Mu Hui,Zhu Xiaojian,Jia Hui,Zhou Lu,Liu Hong
Abstract
Although tyrosine Kinase Inhibitors (TKI) has revolutionized the treatment of chronic myeloid leukemia (CML), patients are not cured with the current therapy modalities. Also, the more recent goal of CML treatment is to induce successful treatment-free remission (TFR) among patients achieving durable deep molecular response (DMR). Together, it is necessary to develop novel, curative treatment strategies. With advancements in understanding the biology of CML, such as dormant Leukemic Stem Cells (LSCs) and impaired immune modulation, a number of agents are now under investigation. This review updates such agents that target LSCs, and together with TKIs, have the potential to eradicate CML. Moreover, we describe the developing immunotherapy for controlling CML.
Reference163 articles.
1. Mechanisms of BCR-ABL in the Pathogenesis of Chronic Myelogenous Leukaemia;Ren;Nat Rev Cancer,2005
2. The Biology of Chronic Myeloid Leukemia;Faderl;N Engl J Med,1999
3. Role of P21 RAS in p210 Bcr-Abl Transformation of Murine Myeloid Cells;Mandanas;Blood,1993
4. Factor Independence of Human Myeloid Leukemia Cell Lines is Associated With Increased Phosphorylation of the Proto-Oncogene Raf-1;Okuda;Exp Hematol,1994
5. Dominant Negative MYC Blocks Transformation by ABL Oncogenes;Sawyers;Cell,1992
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献